With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.